Decoy Therapeutics Inc. (DCOY) Stock Price & Analysis

Decoy Therapeutics Inc. (DCOY) fell 12.82% to USD 5.51 as of June 10, 2026 at 04:40 UTC, according to Nexqual real-time market data.

DCOY last closed at USD 6.32; the session ranged USD 5.06–7 on volume of 17,479 shares. Market capitalization is $2.93M, with a 52-week range of USD 4.32–415.8 (NCM). Source: Nexqual, June 10, 2026 at 04:40 UTC.

Key Statistics (as of June 10, 2026 at 04:40 UTC)

Technical Analysis (DCOY)

Nexqual's technical model rates DCOY "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 04:40 UTC.

Analyst Ratings (DCOY)

Wall Street analysts rate DCOY "None" based on 1 analysts, with a mean price target of USD 30 (range USD 30–30), per Nexqual as of June 10, 2026 at 04:40 UTC.

Earnings (DCOY)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 04:40 UTC.

Financials & Fundamentals (DCOY)

Source: Nexqual, June 10, 2026 at 04:40 UTC.

Financial Health Score (DCOY)

Nexqual rates Decoy Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:40 UTC.

Ownership (DCOY)

Source: Nexqual, June 10, 2026 at 04:40 UTC.

Leadership (DCOY)

Decoy Therapeutics Inc. is led by Frederick E. Pierce (age 63), CEO & Director, per Nexqual as of June 10, 2026 at 04:40 UTC.

Major Backers & Investors (DCOY)

Notable institutional backers of Decoy Therapeutics Inc. include Fidelity, Tower Research Capital LLC (TRC), according to Nexqual as of June 10, 2026 at 04:40 UTC.

Active Investors

Source: Nexqual, June 10, 2026 at 04:40 UTC.

From Decoy Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• The net proceeds from the Offering, including the additional shares of Common Stock, Series A warrants and Series B warrants sold pursuant to the exercise of the Representative's option, after deducting underwriting discounts and commissions and other estimated Offering expenses payable by the Company and excluding any net proceeds from the exercise of the Series A warrants, Series B warrants and pre-funded warrants, were approximately $6.3 million.
• We have received approximately $4.4 million in multiple tranches as we reached specific research milestones, and expect to receive the final tranche of approximately $600,000 in the first half of 2026.
• Continuing to iterate on our Design-Build-Test-Learn loop will generate valuable proprietary data driving in silico models to generate design solutions otherwise unavailable from computational approaches.
• Our hypothesis is that the key to ML/AI-driven drug design value-creation is well-structured, useful, proprietary data and knowledge on which tools to use-not the computational models themselves.

Partnerships

• Market research suggests over 5 million such patients in the U.S. and EU, with an estimated net price of up to $500 per 30-day supply in the U.S. feasible. • Post-infection treatment as an alternative to Paxlovid with a superior DDI profile.
• In connection with the November 2025 Offering, the Company and Equiniti Trust Company, LLC entered into a Warrant Agency Agreement pursuant to which Equiniti agreed to act as warrant agent with respect to the Series A warrants, the Series B warrants and the pre-funded warrants.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:40 UTC. This page is informational and not investment advice.